Emma Andrus, Assistant Editor

This week is Hidradenitis Suppurativa Awareness Week.

More research is needed to specify long-term efficacy of the treatment and its ideal dose.

This week is Hidradenitis Suppurativa Awareness Week.

The IL-23p19 inhibitor demonstrated long-term efficacy and safety.

Certain skin conditions such as atopic dermatitis and psoriasis are associated with sleep disturbances and disorders.

This week is Hidradenitis Suppurativa Awareness Week.

Researchers indicated no existing strategy for detecting skin wrinkles in vitro.

This June, there are several awareness days and month designations supporting patients with dermatologic conditions.

ICYMI, this week we had stories about dermatologic disparities among veterans and LGBTQIA+ patients, pediatric melanoma, a European approval for hidradenitis suppurativa, and more.

Researchers examined the disease while going beyond current diagnostic tools.

Scientists have found a new therapy for the severe inflammatory skin disorder.

The approval makes the drug Europe’s first and only IL-17A inhibitor approved for the condition.

As Pride Month begins, the Dermatology Times® team wants to uplift LGBTQIA+ clinicians, patients, and topics in dermatology.

A public exhibition spotlighting individuals with birthmarks improved participants’ wellbeing and sense of self image.

The phase 3b trial showed improvements to minimal disease activity in adults with the condition.

Researchers conducted a systematic review of pediatric melanoma.

Cryoanesthesia was safe and reduced pain in patients receiving intralesional triamcinolone steroid injections.

This Memorial Day, the Dermatology Times® team is taking the time to spotlight dermatologic disparities and concerns among veterans and active members of the military.

In patients with high levels of VEGF-A and more severe psoriasis, downregulation of blood vessel area is more abrupt.

Coastal regions require environmentally-protective sun protection measures and best practices.

The JAK inhibitor demonstrated promising efficacy and safety.

While receiving checkpoint inhibitor therapy, patients with advanced melanoma benefitted from a telehealth exercise program.

Cream containing epigallocatechin gallate (EGCG) or EGCG combined with L-carnitine yielded a greater anti-sebum effect.

New research into the disease’s pathogenesis may inform future treatment options.

Topline results for the topical sodium channel blocker are expected in 2024.

As many as 1 in 5 patients with psoriasis experience depression as a comorbidity.

Researchers analyzed dermatoses associated with obesity and insulin resistance in pediatric patients.

A recent study supports a degree of correlation between trough serum concentration of infliximab and clinical response to infliximab in patients with the condition.

Among the dozens of sessions to be held at the Symposium for Cosmetic Advances and Laser Education (SCALE) 2023 Meeting in Nashville, Tennessee, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

An ongoing study is evaluating the use of multimodal aesthetics protocol in treating patients with hair loss.